Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide.
Complications associated with insulin-dependent diabetes mellitus (type-1diabetes) primarily represent vascular dysfunction that has its origin in the endothelium. While many of the vascular changes are more accountable in the late stages of type-1diabetes, changes that occur in the early or initial functional stages of this disease may precipitate these later complications. The early stages of type-1diabetes are characterized by a diminished production of both insulin and C-peptide with a significant hyperglycemia. During the last decade numerous speculations and theories have been developed to try to explain the mechanisms responsible for the selective changes in vascular reactivity and/or tone and the vascular permeability changes that characterize the development of type-1diabetes. Much of this research has suggested that hyperglycemia and/or the lack of insulin may mediate the observed functional changes in both endothelial cells and vascular smooth muscle. Recent studies suggest several possible mechanisms that might be involved in the observed decreases in vascular nitric oxide (NO) availability with the development of type-1 diabetes. In addition more recent studies have indicated a direct role for both endogenous insulin and C-peptide in the amelioration of the observed endothelial dysfunction. These results suggest a synergistic action between insulin and C-peptide that facilitates increase NO availability and may suggest new clinical treatment modalities for type-1 diabetes mellitus.
Joshua
Irving G
IG
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292, USA. igjosh01@louisville.edu
Zhang
Qin
Q
Falcone
Jeff C
JC
Bratcher
Adrienne P
AP
Rodriguez
Walter E
WE
Tyagi
Suresh C
SC
D002096:C-Peptide / Q000378:metabolism* / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism* / Q000494:pharmacology; D008954:Models, Biological; D009569:Nitric Oxide / Q000096:biosynthesis / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D002096:C-Peptide; D007328:Insulin; D009569:Nitric Oxide